Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) is among the best stocks with the highest upside potential. Guggenheim assumed coverage on Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) with a “Buy” rating and a price target of $8.00, implying a surge of 146.5% from the current price. The analysts have high expectations for the company’s silevertinib Phase 2 data due in the second half of 2025.
Guggenheim believes silevertinib’s preclinical profile, which is designed for broad-spectrum mutation selectivity over wild-type EGFR, positions Black Diamond Therapeutics, Inc. well to meet the set 50% objective response rate (ORR) and 10-month median progression-free survival (mPFS) metrics. Adding to this are strong second-line response rates after osimertinib treatment that could attract strategic partnerships in the future.
If we consider the company’s year-to-date return, Black Diamond Therapeutics, Inc. has surpassed the market by nearly 40%. For what it’s worth, now is the time to take a position in the stock because when the stock rallies, it could rally hard.
Black Diamond Therapeutics, Inc., headquartered in Cambridge, Massachusetts, is a 2014-formed clinical-stage oncology company that discovers and develops MasterKey therapies for people living with genetically defined tumors.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
